Other analysts have also recently issued reports about the company. Piper Jaffray Cos. assumed coverage on Astrazeneca PLC in a research report on Friday. They set an overweight rating on the stock. Shore Capital reiterated a hold rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. JPMorgan Chase & Co. reissued a neutral rating on shares of Astrazeneca PLC in a report on Monday, August 8th. Argus initiated coverage on Astrazeneca PLC in a report on Tuesday, July 12th. They set a hold rating for the company. Finally, TheStreet raised Astrazeneca PLC from a hold rating to a buy rating in a report on Friday, July 22nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the stock. Astrazeneca PLC currently has a consensus rating of Buy and a consensus target price of $37.49.
Astrazeneca PLC (NYSE:AZN) opened at 33.97 on Friday. The firm has a market capitalization of $85.94 billion, a price-to-earnings ratio of 38.82 and a beta of 0.77. The company’s 50-day moving average price is $33.47 and its 200-day moving average price is $30.50. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. Astrazeneca PLC’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.21 earnings per share. Equities analysts expect that Astrazeneca PLC will post $2.97 EPS for the current fiscal year.
The company also recently announced a dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.
A number of hedge funds have recently modified their holdings of AZN. Norges Bank purchased a new stake in shares of Astrazeneca PLC during the fourth quarter worth approximately $10,211,000. Fisher Asset Management LLC raised its stake in shares of Astrazeneca PLC by 5.3% in the first quarter. Fisher Asset Management LLC now owns 233,409 shares of the company’s stock worth $6,935,000 after buying an additional 11,803 shares in the last quarter. Telemus Capital LLC bought a new stake in shares of Astrazeneca PLC during the first quarter worth approximately $361,000. Commonwealth Equity Services Inc raised its stake in shares of Astrazeneca PLC by 6.5% in the first quarter. Commonwealth Equity Services Inc now owns 88,254 shares of the company’s stock worth $2,485,000 after buying an additional 5,386 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in shares of Astrazeneca PLC by 45.2% in the first quarter. TIAA CREF Investment Management LLC now owns 398,366 shares of the company’s stock worth $11,218,000 after buying an additional 124,066 shares in the last quarter. 11.39% of the stock is owned by institutional investors and hedge funds.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.